NCT01002820View on ClinicalTrials.gov

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

August 31, 2013

Conditions
Epilepsy, Complex Partial
Interventions
DRUG

ganaxolone

liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year

Trial Locations (7)

12208

Albany Medical Center, Dept of Neurology, Albany

19063

Riddle Health Care Center II, Philadelphia

19107

Thomas Jefferson University, Comprehensive Epilepsy Center, Philadelphia

23298

Virginia Commonwealth University, Richmond

40536

University of Kentucky, Dept of Neurology, Lexington

43210

Ohio State University, Columbus

90033

University of Southern California, Dept of Neurology, Los Angeles

Sponsors
All Listed Sponsors
lead

Marinus Pharmaceuticals

INDUSTRY

NCT01002820 - A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601 | Biotech Hunter | Biotech Hunter